{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T15:39:21Z","timestamp":1767109161939,"version":"3.40.3"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T00:00:00Z","timestamp":1742860800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T00:00:00Z","timestamp":1742860800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Genom. Med."],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>In patients with complex congenital heart disease (CHD) pathogenic <jats:italic>SMAD6<\/jats:italic> variants have been described previously. The aim of this study was to analyze if pathogenic <jats:italic>SMAD6<\/jats:italic> variants also occur in patients with CHD associated with pulmonary arterial hypertension (CHD-APAH) or idiopathic PAH. A PAH gene panel with up to 64 genes including <jats:italic>SMAD6<\/jats:italic> was used to sequence 311 patients with idiopathic PAH (IPAH) and 32 with CHD-APAH. In 4 of 32 (12.5%) CHD-APAH and in 2 out of 311 (0.64%) IPAH patients we identified likely pathogenic or rare <jats:italic>SMAD6<\/jats:italic> missense variants. All CHD-APAH patients with a rare <jats:italic>SMAD6<\/jats:italic> variant had complex CHD. One patient had bi-allelic <jats:italic>SMAD6<\/jats:italic> variants, combined pulmonary valve defect and supravalvular aortic stenosis, craniosynostosis and radioulnar synostosis. This is the first description of potentially disease-causing <jats:italic>SMAD6<\/jats:italic> variants in patients with IPAH and complex CHD-APAH. Further studies are needed to assess pathogenesis and prevalence of pathogenic <jats:italic>SMAD6<\/jats:italic> variants in PAH.<\/jats:p>","DOI":"10.1038\/s41525-025-00484-6","type":"journal-article","created":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T02:13:49Z","timestamp":1742955229000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Pathogenic SMAD6 variants in patients with idiopathic and complex congenital heart disease associated pulmonary arterial hypertension"],"prefix":"10.1038","volume":"10","author":[{"given":"Sofia","family":"Karl","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ekkehard","family":"Gr\u00fcnig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Memoona","family":"Shaukat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5855-7667","authenticated-orcid":false,"given":"Matthias","family":"Held","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Apitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabian","family":"von Scheidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralf","family":"Geiger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Halank","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen M.","family":"Olsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marius M.","family":"Hoeper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan C.","family":"Kamp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabor","family":"Kovacs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2834-7466","authenticated-orcid":false,"given":"Horst","family":"Olschewski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans-J\u00fcrgen","family":"Seyfarth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katrin","family":"Milger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralf","family":"Ewert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans","family":"Klose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Egenlauf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Panagiota","family":"Xanthouli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katrin","family":"Hinderhofer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7288-8297","authenticated-orcid":false,"given":"Christina A.","family":"Eichstaedt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,25]]},"reference":[{"key":"484_CR1","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1055\/a-2146-7434","volume":"77","author":"H Kaemmerer","year":"2023","unstructured":"Kaemmerer, H. et al. Pulmonary arterial hypertension in congenital heart disease - Part I. Pneumologie 77, 956\u2013961, https:\/\/doi.org\/10.1055\/a-2146-7434 (2023).","journal-title":"Pneumologie"},{"key":"484_CR2","doi-asserted-by":"publisher","unstructured":"Rosenzweig, E. B. et al. Paediatric pulmonary arterial hypertension: updates on definition, classification, diagnostics and management. Eur. Respir. J. 53. https:\/\/doi.org\/10.1183\/13993003.01916-2018 (2019).","DOI":"10.1183\/13993003.01916-2018"},{"key":"484_CR3","doi-asserted-by":"publisher","first-page":"3618","DOI":"10.1093\/eurheartj\/ehac237","volume":"43","author":"M Humbert","year":"2022","unstructured":"Humbert, M. et al. 2022 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur. Heart J. 43, 3618\u20133731, https:\/\/doi.org\/10.1093\/eurheartj\/ehac237 (2022).","journal-title":"Eur. Heart J."},{"key":"484_CR4","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.ijcard.2006.09.017","volume":"120","author":"MG Duffels","year":"2007","unstructured":"Duffels, M. G. et al. Pulmonary arterial hypertension in congenital heart disease: an epidemiologic perspective from a Dutch registry. Int J. Cardiol. 120, 198\u2013204, https:\/\/doi.org\/10.1016\/j.ijcard.2006.09.017 (2007).","journal-title":"Int J. Cardiol."},{"key":"484_CR5","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1183\/09059180.00004712","volume":"21","author":"M D\u2019Alto","year":"2012","unstructured":"D\u2019Alto, M. & Mahadevan, V. S. Pulmonary arterial hypertension associated with congenital heart disease. Eur. Respir. Rev. 21, 328\u2013337, https:\/\/doi.org\/10.1183\/09059180.00004712 (2012).","journal-title":"Eur. Respir. Rev."},{"key":"484_CR6","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/S2213-2600(18)30409-0","volume":"7","author":"CJ Rhodes","year":"2019","unstructured":"Rhodes, C. J. et al. Genetic determinants of risk in pulmonary arterial hypertension: international genome-wide association studies and meta-analysis. Lancet Respir. Med. 7, 227\u2013238, https:\/\/doi.org\/10.1016\/S2213-2600(18)30409-0 (2019).","journal-title":"Lancet Respir. Med."},{"key":"484_CR7","doi-asserted-by":"publisher","first-page":"2201471","DOI":"10.1183\/13993003.01471-2022","volume":"61","author":"CA Eichstaedt","year":"2023","unstructured":"Eichstaedt, C. A. et al. Genetic counselling and testing in pulmonary arterial hypertension -A consensus statement on behalf of the International Consortium for Genetic Studies in PAH. Eur. Respir. J. 61, 2201471, https:\/\/doi.org\/10.1183\/13993003.01471-2022 (2023).","journal-title":"Eur. Respir. J."},{"key":"484_CR8","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s12931-022-01987-x","volume":"23","author":"CA Eichstaedt","year":"2022","unstructured":"Eichstaedt, C. A. et al. Gene panel diagnostics reveals new pathogenic variants in pulmonary arterial hypertension. Respir. Res. 23, 74, https:\/\/doi.org\/10.1186\/s12931-022-01987-x (2022).","journal-title":"Respir. Res."},{"key":"484_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.gim.2023.100925","volume":"25","author":"CL Welch","year":"2023","unstructured":"Welch, C. L. et al. Defining the clinical validity of genes reported to cause pulmonary arterial hypertension. Genet. Med. 25, 100925, https:\/\/doi.org\/10.1016\/j.gim.2023.100925 (2023).","journal-title":"Genet. Med."},{"key":"484_CR10","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/s41525-022-00338-5","volume":"7","author":"I Luyckx","year":"2022","unstructured":"Luyckx, I., Verstraeten, A., Goumans, M. J. & Loeys, B. SMAD6-deficiency in human genetic disorders. NPJ Genom. Med 7, 68, https:\/\/doi.org\/10.1038\/s41525-022-00338-5 (2022).","journal-title":"NPJ Genom. Med"},{"key":"484_CR11","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1002\/humu.22030","volume":"33","author":"HL Tan","year":"2012","unstructured":"Tan, H. L. et al. Nonsynonymous variants in the SMAD6 gene predispose to congenital cardiovascular malformation. Hum. Mutat. 33, 720\u2013727, https:\/\/doi.org\/10.1002\/humu.22030 (2012).","journal-title":"Hum. Mutat."},{"key":"484_CR12","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1038\/ng.3970","volume":"49","author":"SC Jin","year":"2017","unstructured":"Jin, S. C. et al. Contribution of rare inherited and de novo variants in 2,871 congenital heart disease probands. Nat. Genet 49, 1593\u20131601, https:\/\/doi.org\/10.1038\/ng.3970 (2017).","journal-title":"Nat. Genet"},{"key":"484_CR13","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1038\/s41431-019-0363-z","volume":"27","author":"I Luyckx","year":"2019","unstructured":"Luyckx, I. et al. Confirmation of the role of pathogenic SMAD6 variants in bicuspid aortic valve-related aortopathy. Eur. J. Hum. Genet 27, 1044\u20131053, https:\/\/doi.org\/10.1038\/s41431-019-0363-z (2019).","journal-title":"Eur. J. Hum. Genet"},{"key":"484_CR14","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1038\/s41436-020-0817-2","volume":"22","author":"E Calpena","year":"2020","unstructured":"Calpena, E. et al. SMAD6 variants in craniosynostosis: genotype and phenotype evaluation. Genet Med. 22, 1498\u20131506, https:\/\/doi.org\/10.1038\/s41436-020-0817-2 (2020).","journal-title":"Genet Med."},{"key":"484_CR15","doi-asserted-by":"publisher","DOI":"10.1002\/mgg3.1850","volume":"10","author":"F Shen","year":"2022","unstructured":"Shen, F. et al. A genotype and phenotype analysis of SMAD6 mutant patients with radioulnar synostosis. Mol. Genet Genom. Med. 10, e1850, https:\/\/doi.org\/10.1002\/mgg3.1850 (2022).","journal-title":"Mol. Genet Genom. Med."},{"key":"484_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-018-0566-x","volume":"10","author":"N Zhu","year":"2018","unstructured":"Zhu, N. et al. Rare variants in SOX17 are associated with pulmonary arterial hypertension with congenital heart disease. Genome Med. 10, 56, https:\/\/doi.org\/10.1186\/s13073-018-0566-x (2018).","journal-title":"Genome Med."},{"key":"484_CR17","doi-asserted-by":"publisher","unstructured":"Galambos, C. et al. Phenotype characterisation of TBX4 mutation and deletion carriers with neonatal and paediatric pulmonary hypertension. Eur. Respir. J. 54. https:\/\/doi.org\/10.1183\/13993003.01965-2018 (2019).","DOI":"10.1183\/13993003.01965-2018"},{"key":"484_CR18","doi-asserted-by":"publisher","unstructured":"Wang, T. M. et al. SOX17 Loss-of-Function Mutation Underlying Familial Pulmonary Arterial Hypertension. Int Heart J. https:\/\/doi.org\/10.1536\/ihj.20-711 (2021).","DOI":"10.1536\/ihj.20-711"},{"key":"484_CR19","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1007\/s00414-018-1890-9","volume":"132","author":"J Zheng","year":"2018","unstructured":"Zheng, J. et al. Genetic diagnosis of acute aortic dissection in South China Han population using next-generation sequencing. Int J. Leg. Med. 132, 1273\u20131280, https:\/\/doi.org\/10.1007\/s00414-018-1890-9 (2018).","journal-title":"Int J. Leg. Med."},{"key":"484_CR20","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.jmgm.2008.12.003","volume":"27","author":"P Makkar","year":"2009","unstructured":"Makkar, P., Metpally, R. P. R., Sangadala, S. & Reddy, B. V. B. Modeling and analysis of MH1 domain of Smads and their interaction with promoter DNA sequence motif. J. Mol. Graph. Model. 27, 803\u2013812, https:\/\/doi.org\/10.1016\/j.jmgm.2008.12.003 (2009).","journal-title":"J. Mol. Graph. Model."},{"key":"484_CR21","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.amjcard.2013.09.032","volume":"113","author":"RJ Barst","year":"2014","unstructured":"Barst, R. J., Ivy, D. D., Foreman, A. J., McGoon, M. D. & Rosenzweig, E. B. Four- and seven-year outcomes of patients with congenital heart disease-associated pulmonary arterial hypertension (from the REVEAL Registry). Am. J. Cardiol. 113, 147\u2013155, https:\/\/doi.org\/10.1016\/j.amjcard.2013.09.032 (2014).","journal-title":"Am. J. Cardiol."},{"key":"484_CR22","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s00439-019-02011-x","volume":"138","author":"K Kloth","year":"2019","unstructured":"Kloth, K. et al. Biallelic variants in SMAD6 are associated with a complex cardiovascular phenotype. Hum. Genet 138, 625\u2013634, https:\/\/doi.org\/10.1007\/s00439-019-02011-x (2019).","journal-title":"Hum. Genet"},{"key":"484_CR23","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1136\/jmg-2023-109151","volume":"61","author":"I Luyckx","year":"2024","unstructured":"Luyckx, I. et al. Homozygous SMAD6 variants in two unrelated patients with craniosynostosis and radioulnar synostosis. J. Med Genet 61, 363\u2013368, https:\/\/doi.org\/10.1136\/jmg-2023-109151 (2024).","journal-title":"J. Med Genet"},{"key":"484_CR24","doi-asserted-by":"publisher","DOI":"10.1002\/mgg3.620","volume":"7","author":"JE Park","year":"2019","unstructured":"Park, J. E. et al. A novel SMAD6 variant in a patient with severely calcified bicuspid aortic valve and thoracic aortic aneurysm. Mol. Genet Genom. Med. 7, e620, https:\/\/doi.org\/10.1002\/mgg3.620 (2019).","journal-title":"Mol. Genet Genom. Med."},{"key":"484_CR25","doi-asserted-by":"publisher","first-page":"400","DOI":"10.3389\/fphys.2017.00400","volume":"8","author":"E Gillis","year":"2017","unstructured":"Gillis, E. et al. Candidate gene resequencing in a large bicuspid aortic valve-associated thoracic aortic aneurysm cohort: SMAD6 as an important contributor. Front Physiol. 8, 400, https:\/\/doi.org\/10.3389\/fphys.2017.00400 (2017).","journal-title":"Front Physiol."},{"key":"484_CR26","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1038\/39355","volume":"389","author":"T Imamura","year":"1997","unstructured":"Imamura, T. et al. Smad6 inhibits signalling by the TGF-\u03b2 superfamily. Nature 389, 622\u2013626, https:\/\/doi.org\/10.1038\/39355 (1997).","journal-title":"Nature"},{"key":"484_CR27","doi-asserted-by":"publisher","first-page":"20603","DOI":"10.1074\/jbc.m702100200","volume":"282","author":"K Goto","year":"2007","unstructured":"Goto, K., Kamiya, Y., Imamura, T., Miyazono, K. & Miyazawa, K. Selective inhibitory effects of Smad6 on bone morphogenetic protein type I receptors. J. Biol. Chem. 282, 20603\u201320611, https:\/\/doi.org\/10.1074\/jbc.m702100200 (2007).","journal-title":"J. Biol. Chem."},{"key":"484_CR28","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1006\/bbrc.1998.9170","volume":"249","author":"M Afrakhte","year":"1998","unstructured":"Afrakhte, M. et al. Induction of inhibitory Smad6 and Smad7 mRNA by TGF-beta family members. Biochem. Biophys. Res. Commun. 249, 505\u2013511, https:\/\/doi.org\/10.1006\/bbrc.1998.9170 (1998).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"484_CR29","doi-asserted-by":"publisher","first-page":"2809","DOI":"10.1091\/mbc.e02-07-0441","volume":"14","author":"G Murakami","year":"2003","unstructured":"Murakami, G., Watabe, T., Takaoka, K., Miyazono, K. & Imamura, T. Cooperative inhibition of bone morphogenetic protein signaling by Smurf1 and inhibitory Smads. Mol. Biol. Cell 14, 2809\u20132817, https:\/\/doi.org\/10.1091\/mbc.e02-07-0441 (2003).","journal-title":"Mol. Biol. Cell"},{"key":"484_CR30","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s10456-021-09777-7","volume":"24","author":"DL Ruter","year":"2021","unstructured":"Ruter, D. L. et al. SMAD6 transduces endothelial cell flow responses required for blood vessel homeostasis. Angiogenesis 24, 387\u2013398, https:\/\/doi.org\/10.1007\/s10456-021-09777-7 (2021).","journal-title":"Angiogenesis"},{"key":"484_CR31","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1016\/j.ajpath.2015.03.019","volume":"185","author":"RB Good","year":"2015","unstructured":"Good, R. B. et al. Endothelial to mesenchymal transition contributes to endothelial dysfunction in pulmonary arterial hypertension. Am. J. Pathol. 185, 1850\u20131858, https:\/\/doi.org\/10.1016\/j.ajpath.2015.03.019 (2015).","journal-title":"Am. J. Pathol."},{"key":"484_CR32","doi-asserted-by":"publisher","first-page":"re8","DOI":"10.1126\/scisignal.2005189","volume":"7","author":"DM Gonzalez","year":"2014","unstructured":"Gonzalez, D. M. & Medici, D. Signaling mechanisms of the epithelial-mesenchymal transition. Sci. Signal 7, re8, https:\/\/doi.org\/10.1126\/scisignal.2005189 (2014).","journal-title":"Sci. Signal"},{"key":"484_CR33","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1161\/strokeaha.120.030046","volume":"51","author":"W Fu","year":"2020","unstructured":"Fu, W. et al. Mesenchymal behavior of the endothelium promoted by SMAD6 downregulation is associated with brain arteriovenous malformation microhemorrhage. Stroke 51, 2197\u20132207, https:\/\/doi.org\/10.1161\/strokeaha.120.030046 (2020).","journal-title":"Stroke"},{"key":"484_CR34","doi-asserted-by":"publisher","unstructured":"Ma, J., Sanchez-Duffhues, G., Goumans, M.-J. & ten Dijke, P. TGF-\u03b2-induced endothelial to mesenchymal transition in disease and tissue engineering. Frontiers in Cell and Developmental Biology 8. https:\/\/doi.org\/10.3389\/fcell.2020.00260 (2020)","DOI":"10.3389\/fcell.2020.00260"},{"key":"484_CR35","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1161\/circulationaha.114.008750","volume":"131","author":"B Ranchoux","year":"2015","unstructured":"Ranchoux, B. et al. Endothelial-to-mesenchymal transition in pulmonary hypertension. Circulation 131, 1006\u20131018, https:\/\/doi.org\/10.1161\/circulationaha.114.008750 (2015).","journal-title":"Circulation"},{"key":"484_CR36","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.diff.2012.04.003","volume":"84","author":"BPT Kruithof","year":"2012","unstructured":"Kruithof, B. P. T., Duim, S. N., Moerkamp, A. T. & Goumans, M.-J. TGF\u03b2 and BMP signaling in cardiac cushion formation: Lessons from mice and chicken. Differentiation 84, 89\u2013102, https:\/\/doi.org\/10.1016\/j.diff.2012.04.003 (2012).","journal-title":"Differentiation"},{"key":"484_CR37","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1038\/72835","volume":"24","author":"KM Galvin","year":"2000","unstructured":"Galvin, K. M. et al. A role for Smad6 in development and homeostasis of the cardiovascular system. Nat. Genet. 24, 171\u2013174, https:\/\/doi.org\/10.1038\/72835 (2000).","journal-title":"Nat. Genet."},{"key":"484_CR38","doi-asserted-by":"publisher","first-page":"e81","DOI":"10.1016\/j.jacc.2018.08.1029","volume":"73","author":"KK Stout","year":"2019","unstructured":"Stout, K. K. et al. 2018 AHA\/ACC Guideline for the Management of Adults With Congenital Heart Disease: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. J. Am. Coll. Cardiol. 73, e81\u2013e192, https:\/\/doi.org\/10.1016\/j.jacc.2018.08.1029 (2019).","journal-title":"J. Am. Coll. Cardiol."},{"key":"484_CR39","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1093\/eurheartj\/ehaa554","volume":"42","author":"H Baumgartner","year":"2021","unstructured":"Baumgartner, H. et al. 2020 ESC Guidelines for the management of adult congenital heart disease. Eur. Heart J. 42, 563\u2013645, https:\/\/doi.org\/10.1093\/eurheartj\/ehaa554 (2021).","journal-title":"Eur. Heart J."},{"key":"484_CR40","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards, S. et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet. Med. 17, 405\u2013424, https:\/\/doi.org\/10.1038\/gim.2015.30 (2015).","journal-title":"Genet. Med."},{"key":"484_CR41","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1002\/humu.20880","volume":"29","author":"SE Plon","year":"2008","unstructured":"Plon, S. E. et al. Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results. Hum. Mutat. 29, 1282\u20131291, https:\/\/doi.org\/10.1002\/humu.20880 (2008).","journal-title":"Hum. Mutat."},{"key":"484_CR42","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1002\/humu.24088","volume":"41","author":"SV Tavtigian","year":"2020","unstructured":"Tavtigian, S. V., Harrison, S. M., Boucher, K. M. & Biesecker, L. G. Fitting a naturally scaled point system to the ACMG\/AMP variant classification guidelines. Hum. Mutat. 41, 1734\u20131737, https:\/\/doi.org\/10.1002\/humu.24088 (2020).","journal-title":"Hum. Mutat."}],"container-title":["npj Genomic Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41525-025-00484-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41525-025-00484-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41525-025-00484-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T02:13:51Z","timestamp":1742955231000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41525-025-00484-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,25]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["484"],"URL":"https:\/\/doi.org\/10.1038\/s41525-025-00484-6","relation":{},"ISSN":["2056-7944"],"issn-type":[{"type":"electronic","value":"2056-7944"}],"subject":[],"published":{"date-parts":[[2025,3,25]]},"assertion":[{"value":"2 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"E.G., K.H., and CA.E. are the inventors of the issued European patent \u201cGene panel specific for pulmonary hypertension and its uses\u201d (EP3507380). The patent applicants are the Thoraxklinik-Heidelberg gGmbH and the Ruprecht-Karls-Universit\u00e4t Heidelberg. The panel was used for the NGS sequencing of all patients in this study. E.G. received fees for lectures and\/or consultations from Actelion, Bayer, GSK, Janssen, MSD, Pfizer and United Therapeutics. C.A.E. received honoraria for lectures and presentations from OMT and MSD, consulting fees from MSD outside the submitted work. M.a.H. received consulting frees from Bayer Healthcare, Bristol Myers Squibb, Boehringer Ingelheim, Janssen, MSD, Pfizer; honoraria for lectures from: AstraZeneca, Bayer HealthCare, Berlin Chemie, Boehringer Ingelheim, Bristol Myers Squibb, Daichi Sankyo, Janssen, MSD, Pfizer, Santis outside the submitted work. CA received honoraria from Janssen outside the submitted work. M.i.H. received honoraria for lectures and\/or consulting from AstraZeneca, Janssen und MSD outside the submitted work. K.M.O. served as consultant or speaker for Acceleron Pharma, Inc., Actelion Pharmaceuticals, AOP Orphan, Bayer Healthcare, Ferrer, GossamerBio, Janssen Global Services, LLC, and Merck & Co., Inc. (Rahway, NJ, USA) (paid to self) outside the submitted work. M.M.H. served as consultant or speaker for Acceleron Pharma, Inc., Actelion Pharmaceuticals, AOP Orphan, Bayer Healthcare, Ferrer, GossamerBio, Janssen Global Services, LLC, and Merck & Co., Inc. (Rahway, NJ, USA) (paid to self) outside the submitted work. G.K. received honoraria for lectures and\/or consulting from Janssen, Boehringer-Ingelheim, AstraZeneca, Bayer, MSD, Chiesi, Ferrer, AOP outside the submitted work. H.O. received honoraria for lectures and\/or consulting from AstraZeneca, Bayer, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Iqvia, Janssen, MedUpdate, Menarini, MSD, Novartis and Pfizer outside the submitted work. H.J.S. received honoraria for lectures and\/or presentations from Janssen-Cilag and Ferrer outside the submitted work. K.M. received honoraria for lectures and\/or consulting from AOP, AstraZeneca, Chiesi, GSK, Janssen, MSD, Novartis, Sanofi outside the submitted work. R.E. received honoraria fees for consulting and\/or lectures from AstraZeneca, AOP Orphan, Bayer, Berlin Chemie, GSK, Janssen Pharmaceutical Companies of Johnson & Johnson, LungPacer, Novartis, Merc, OMT and Pfizer, and research support from OMT and Boehringer Ingelheim outside the submitted work. H.K. received honoraria for lectures and\/or consulting Bayer, Gossamer Bio, Janssen Cilag, MSD, Orphacare und Pfizer, OMT, United Therapeutics outside the submitted work. B.E. received travel fees, consulting fees, speaking fees, and\/or honoraria from Actelion, MSD, Bayer and OMT, outside the submitted work. P.X. received speaker fees from Janssen, MSD and OMT outside the submitted work. F.v.S., J.C.K., K.H., M.S., R.G., S.K.: nothing to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"28"}}